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Abstract  29 
Background 30 
The aim of this study was to compare unicompartmental and total knee replacement (UKR and TKR), 31 
emulating the design of the Total or Partial Knee Arthroplasty Trial (TOPKAT) using routinely-32 
collected data. The primary outcome in TOPKAT was patient-reported outcomes, with secondary 33 
outcomes including post-operative complications and implant survival.  34 
Methods 35 
Five US and UK healthcare databases, part of the Observational Health Data Sciences and 36 
Informatics (OHDSI) network, were analysed. Opioid use from 91 to 365 days after surgery, as a 37 
proxy for persistent pain, was assessed. Post-operative complications (venous thromboembolism, 38 
infection, readmission, and mortality) were considered over 60 days following surgery and implant 39 
survival over five years following surgery. Propensity score matched Cox proportional hazards 40 
models were fitted for each outcome. Calibrated hazard ratios (cHRs) were generated for each 41 
database to account for observed differences in control outcomes and these were combined using 42 
meta-analysis. 43 
Findings 44 
In total, 32,379 and 250,377 individuals who received UKR and TKR were matched and included in 45 
the analysis. UKR was associated with a reduced risk of post-operative opioid use (cHR from meta-46 
analysis: 0.81 (95% CI: 0.73 to 0.90)). UKR was also associated with a reduced risk of venous 47 
thromboembolism (cHR: 0.62 (0.36 to 0.95)), but little difference was seen for infection (cHR: 0.85 48 
(0.51 to 1.37)) and readmission (cHR: 0.79 (0.47 to 1.25)). There was insufficient evidence to 49 
conclude there was a reduction in risk of mortality. UKR was also associated with an increased risk of 50 
revision (cHR: 1.64 (1.40 to 1.94)).  51 
Interpretation 52 
UKR was associated with a reduced risk of opioid use compared to TKR, which may indicate a 53 
reduced risk of persistent pain after surgery. UKR was associated with a lower risk of venous 54 
thromboembolism. UKR was also, however, associated with an increased risk of revision compared 55 
to TKR. 56 
 57 
Funding  58 
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Research in context 61 
Evidence before this study 62 
Prior research has found unicompartmental and total knee replacement (UKR and TKR) to result in 63 
broadly similar patient-reported outcomes, UKR to have a lower risk of some post-operative 64 
complications, notably venous thromboembolism, infection, and mortality, but TKR to have a lower 65 
risk of revision procedures. A recent randomised controlled trial, the Total or Partial Knee 66 
Arthroplasty Trial (TOPKAT), compared UKR and TKR, with 264 patients randomised into each arm of 67 
the trial. The primary outcome for TOPKAT was post-operative patient-reported outcomes, with 68 
secondary outcomes including post-operative complications and implant survival. Consistent with 69 
previous observational studies, post-operative patient-reported outcomes were similar at 5 years 70 
and fewer complications seen for those who had UKR. However, rates of revision were seen to be 71 
similar for UKR and TKR at 5 years. Direct comparisons between the randomised evidence from 72 
TOPKAT and observational studies are, however, made difficult though due to differences in study 73 
designs. 74 
Added value of this study 75 
This study emulates the TOPKAT design using routinely-collected data. Where possible, similar 76 
eligibility criteria were specified and outcomes assessed in a similar manner. Patient-reported 77 
outcomes (the primary outcome in TOPKAT) were not available, and so opioid prescriptions were 78 
used as a proxy for persistent pain following surgery. Post-operative complications and implant 79 
survival were also assessed. The findings from this study will provide further evidence to inform 80 
considerations of the relative merits of UKR and TKR. 81 
Implications of all the available evidence 82 
In this study, UKR was associated with a reduced risk of post-operative opioid use between 91 to 365 83 
days after surgery relative to TKR, and this may indicate a reduced risk of persistent pain after UKR. 84 
As seen in this study and in previous research, UKR also appears to have a lower risk of venous 85 
thromboembolism compared to TKR. However, while revision rates were similar for UKR and TKR in 86 
TOPKAT, the findings from this study support that of previous observational research showing UKR 87 
to have an increased risk of revision. 88 
 89 
 90 
  91 
Introduction 92 
Knee replacement is one of the most common surgical procedures and typically leads to substantial 93 
improvements in pain, function and quality of life.1 However, there is variation in how knee 94 
replacements are performed. One area of particular uncertainty is around whether to use 95 
unicompartmental or total knee replacement (UKR or TKR) for those individuals with osteoarthritis 96 
confined to a single compartment of the knee.  While all the compartments of the joint are replaced 97 
in TKR, only the affected part of the joint is replaced in UKR. 98 
With patient-reported pain and function key indications for knee and hip replacement, it follows that 99 
they should also be considered as a key measure of the effectiveness of surgery. Previous research 100 
has generally found UKR and TKR to result in broadly similar gains in patient-reported outcomes after 101 
surgery.2 Both UKR and TKR are major orthopaedic procedures and so are accompanied by a risk of 102 
post-operative complications. Findings from previous research suggests that UKR, which is a quicker 103 
and less-invasive procedure relative to TKR, may have a lower risk of some post-operative 104 
complications, notably venous thromboembolism, infection, and mortality.2 As well as the short-term 105 
risk of post-operative complications, patients who have had a knee and hip replacement have a long-106 
term risk of revision surgery, in which implant components are removed, added or exchanged. 107 
Revision procedures are associated with significant morbidity for individuals, with those undergoing 108 
revision surgery generally reporting worse patient-reported outcomes before and after revision 109 
procedures compared with those undergoing primary procedures.3 Observational research has 110 
consistently found UKR to have a higher risk of revision procedures compared to TKR, with the 111 
increased risk maintained over 25 years after the primary procedure.2,4 112 
In a recently published randomised controlled trial comparing UKR and TKR, the Total or Partial Knee 113 
Arthroplasty Trial (TOPKAT), 264 patients were randomly assigned UKR with another 264 assigned 114 
TKR, with 245 and 269 going on to receive UKR and TKR, respectively. Surgeons performing the 115 
procedures were either ‘equipoise’ surgeons who performed both surgeries, or ‘expertise’ surgeons 116 
who performed only one of the procedures while another ‘expertise’ surgeon in the same centre 117 
performed the other. To perform a given procedure surgeons needed to have been practising it for 118 
at a year and to have performed it at least ten times in the previous year.5 The trial was powered to 119 
assess the primary outcome which was self-reported pain and function, as measured by the Oxford 120 
Knee Score (OKS).5 Both groups achieved substantial improvements in OKS relative to baseline 121 
scores, with the gains broadly similar across the two comparator groups. Post-operative 122 
complications and implant survival were also assessed in TOPKAT as secondary outcomes. Fewer 123 
individuals had a post-operative complication after UKR compared to TKR. In contrast to the 124 
previous observational research, UKR and TKR were also seen to have similar rates of revision after 5 125 
years in the trial.6  126 
The aim of this study was to emulate the TOPKAT trial design using routinely-collected data, so as to 127 
answer the same causal question. A study which uses routinely-collected data to emulate the ‘target 128 
trial’ should be harmonised, with similar study designs applied to allow for meaningful 129 
comparisons.7,8 The primary outcome was patient-reported pain and function. As this was not 130 
possible, the effect of type of procedure (UKR or TKR) on persistent pain after surgery was 131 
considered. Secondary outcomes in the target trial included post-operative complications and 132 
implant survival, and these were also assessed in this study. 133 
Methods 134 
A network cohort study was conducted across 5 observational health care databases from the US 135 
and the UK. The study period was from 1 January 2005 to 30 April 2018. The study was designed and 136 
performed before the results of TOPKAT became available. To promote transparency and 137 
reproducibility, the full study protocol, all code lists used, and source code for the study execution 138 
are publicly available at 139 
https://github.com/OHDSI/StudyProtocols/tree/master/UkaTkaSafetyEffectiveness.   140 
Data sources 141 
We used data from the following 5 healthcare databases: 1) IBM MarketScan® Commercial Database 142 
(CCAE), which includes claims data from individuals in the United States (US) enrolled in employer-143 
sponsored insurance health plans; 2) IBM MarketScan® Medicare Supplemental and Coordination of 144 
Benefits Database (MDCR), which includes claims data from older adults in the US with primary or 145 
Medicare supplemental coverage through privately insured fee-for-service, point-of-service, or 146 
capitated health plans; 3) Optum® de-identified Clinformatics® Datamart, Extended - Date of Death 147 
(Optum), which includes US patients fully insured in commercial plans or covered with 148 
administrative services only and commercial Medicare; 4) PharMetrics™ Plus (PharMetrics), an 149 
adjudicated claims database of privately insured US individuals; and, 5) The Health Improvement 150 
Network (THIN), which includes pseudonymised electronic primary care medical records from a 151 
representative sample of UK inhabitants. These 5 databases were converted to the Observational 152 
Medical Outcomes Partnership (OMOP) Common Data Model (CDM), which enables consistent 153 
application of analyses across disparate data sources.9  154 
Exposure cohorts 155 
Individuals who underwent either a UKR or TKR were identified. Study participants were required to 156 
have data captured over at least the year prior to surgery. We excluded patients using published 157 
exclusion criteria of TOPKAT,5 with individuals required to be aged 40 or over at surgery, and have no 158 
prior evidence of knee arthroplasty, knee fracture, knee surgery except for diagnostic procedures, 159 
rheumatoid arthritis, inflammatory arthropathies, or septic arthritis. In addition, patients with spine, 160 
hip, or foot pathology in the year prior to surgery were also excluded. These criteria were intended 161 
to identify patients who were eligible for either type of knee replacement, and exclude patients who 162 
were not indicated for either UKR or TKR.  163 
Outcome definitions  164 
Relating to patient-reported outcomes which were the primary outcome in the target trial, 165 
persistent pain after surgery was assessed using opioid use (identified by a written or dispensed 166 
opioid prescription) as a proxy, with a time-at-risk 91 days after surgery to 1 year after surgery. The 167 
90-day washout period intended to exclude those prescriptions which could be considered as a 168 
routine consequence of undergoing surgery. Opioid use was assessed in all databases. 169 
Post-operative complications assessed were symptomatic venous thromboembolism (identified by a 170 
diagnosis code of either deep vein thrombosis or pulmonary embolism), infection (identified by a 171 
diagnosis of an infection that could be associated with knee replacement), readmission (identified by 172 
an inpatient or emergency room visit for any cause), and all-cause mortality. Venous 173 
thromboembolism and infection were assessed in all databases, readmission in CCAE, Optum, and 174 
MDCR, and mortality in Optum and THIN. Time-at-risk for post-operative complications was from the 175 
date of surgery to 60 days after surgery. Meanwhile, implant survival was assessed in terms of 176 
revision (identified by a relevant procedure code) with the time-at-risk from date of surgery to 5 177 
years after surgery. Implant survival was assessed in all databases. 178 
Statistical methods 179 
Propensity score matching was used to minimise confounding by observed characteristics.10 A large 180 
set of patient-level baseline covariates (representing demographics, health services utilization, and 181 
prior diagnoses, medications, lab tests, and procedures) were constructed for propensity score 182 
model input. These covariates were assessed over varying time windows relative to an individual’s 183 
index date, with them identified from 30 days, 365 days, 1095 days and all available days prior to the 184 
index date. Propensity scores were generated using a large-scale regularized logistic regression fitted 185 
with a Laplace prior (LASSO) and the optimal hyperparameter determined through 10-fold cross 186 
validation in order to balance baseline covariates while avoiding overfitting.11,12 In the primary 187 
analyses, patients were matched on the propensity score using variable-ratio matching with a 188 
maximum ratio of UKR to TKR of 1:10. The balance of propensity score-matched cohorts was 189 
evaluated using standardized mean difference, with values of <0.1 taken to indicate negligible group 190 
differences.13 Propensity score distribution plots, normalized to the preference scale, were used to 191 
evaluate empirical equipoise.14  192 
Cox proportional hazards models, with procedure type (UKR or TKR) as the sole explanatory variable 193 
and conditioned on the matched sets, were fitted to estimate the average treatment effect among 194 
UKR patients on the outcomes listed above. Proportionality of hazards was checked visually using 195 
Kaplan-Meier plots. Cox models were also estimated for 39 pre-specified negative control conditions 196 
(detailed in Appendix Table A1) believed to have no causal relationship with type of knee 197 
replacement. To control for residual confounding, hazard ratios (HRs) for the outcomes of interest 198 
were calibrated based on the estimated residual error from negative control outcomes and synthetic 199 
positive control outcomes.15,16 Empirical calibration is a process whereby the residual error of an 200 
estimator is quantified and incorporated into a calibrated version of the estimator. The calibrated HR 201 
(cHR), in this case, reflects the distribution of estimates on the negative control outcomes. For 202 
example, if the negative control estimates are on average greater than the null, an increased risk for 203 
the outcome of interested will be attenuated following calibration. The cHRs were only estimated if 204 
a sufficient number of control outcomes were observed during a given time-at-risk window. Each 205 
analysis was conducted separately in each database.  206 
Findings across databases were combined using meta-analysis, with the inverse variance random-207 
effects approach used.17 At the request of peer review, results were meta-analysed for each of the 208 
outcomes. An I2 above 40% can, however, be taken to indicate substantial heterogeneity across 209 
databases. 18 Estimates for negative and positive controls were pooled before performing empirical 210 
calibration on the pooled estimates. 211 
Sensitivity analyses 212 
Pre-specified sensitivity analyses were run for each of the outcomes of interest, with variations of 213 
cohort definitions, time-at-risk, and approaches to matching (Appendix Table 2). 214 
Role of the funding source 215 
The funder of the study had no role in study design, data collection, data analysis, data 216 
interpretation, or writing of the report 217 
Results 218 
32,379 individuals who had UKR and 250,377 who had TKR were matched using propensity scores 219 
(see Appendix Figure A1 for study flowcharts). Prior to matching, individuals undergoing UKR were 220 
younger and healthier than those undergoing TKR (Appendix Table A3). Diagnostics for propensity 221 
score matching and control outcome findings are summarised in Appendix Figure A2. After 222 
matching, both cohorts appeared largely comparable in terms of observed characteristics (Table 1 223 
and Appendix Figure 2). Individuals in the matched CCAE, Optum, and PharMetrics cohorts were 224 
generally younger and had fewer comorbidities compared to THIN and, in particular, MDCR. THIN 225 
covered the broadest age range of individuals. Pre-operative opioid use was well balanced for the 226 
comparator groups, with between 30% to 45% of individuals classified as an opioid user before 227 
surgery. 228 
UKR was consistently associated with a reduced risk of opioid use after surgery relative to TKR, with 229 
cHRs for the use of opioids in the 3 to 12 months post-surgery ranging from 0.70 (0.57 to 0.90) for 230 
THIN to 0.86 (0.78 to 0.96) for Optum. The estimate from meta-analysis was 0.81 (0.73 to 0.90). The 231 
cumulative incidence of opioid use in the 3 to 12 months post-surgery was around 35% to 40% for 232 
UKR and about 5 percentage points higher for TKR in the 4 databases from the US. Opioid use was 233 
around 20% for UKR and 25% for TKR in the database from the UK (Appendix Figure A2). These 234 
findings were generally similar across sensitivity analyses. When considered up to 5 years, UKR was 235 
still associated with a reduced risk of opioid use, but the estimated effects were slightly attenuated 236 
with cHRs ranging from 0.86 (0.78 to 0.96) for CCAE to 0.90 (0.82 to 1.02) for MDCR, with no meta-237 
analysis performed for these outcomes. 238 
UKR was consistently associated with a lower risk of venous thromboembolism compared to TKR. 239 
The cHRs ranged between 0.47 (0.32 to 0.71) for MDCR and 0.76 (0.59 to 0.99) for CCAE, with the 240 
estimate from meta-analysis 0.62 (0.36 to 0.95), see Figure 1. Point estimates for risk of infection 241 
and readmission varied from a protective effect for UKR to no difference between the procedures, 242 
with cHRs for infection ranged from 0.73 (0.44 to 1.24) for PharMetrics to 1.04 (0.77 to 1.43) for 243 
CCAE, while cHRs for readmission ranged from 0.66 (0.46 to 0.97) for MDCR to 0.99 (0.71 to 1.48) for 244 
Optum (Figure 1). Estimates from meta-analysis were 0.85 (0.51 to 1.37) and 0.79 (0.47 to 1.25) for 245 
infection and readmission, respectively, although in both cases I2 was above 0.5. Finally, there was 246 
little evidence of an association between procedure and mortality, with a cHR of 1.26 (0.55 to 3.09) 247 
in Optum and a HR of 0.51 (0.03 to 2.51) in THIN. Findings were broadly similar across sensitivity 248 
analyses. There was stronger evidence, however, that UKR was associated with a reduced risk of 249 
readmission when considered over the year following surgery rather than 60 days in CCAE and 250 
MDCR, cHRs 0.75 (0.66 to 0.86) and 0.76 (0.64 to 0.93), respectively. 251 
UKR was consistently associated with an increased risk of revision compared to TKR over the five 252 
years following surgery (Figure 1), with cHRs ranging from 1.48 (1.25 to 1.83) for PharMetrics to 2.16 253 
(1.63 to 3.15) for MDCR. The estimate from meta-analysis was 1.64 (1.40 to 1.94), although I2 was 254 
0.5. After 5 years, implant survival was generally around 97.5% to 95% for TKR and 95% to 92.5% 255 
following UKR (Appendix Figure A3). These findings were similar across the various sensitivity 256 
analyses considered. 257 
Results for the primary analysis and each sensitivity analysis are detailed in Appendix Table A4. 258 
These can also be viewed, along with study flow charts, characteristics of study participants before 259 
and after matching, and propensity score distributions, using the interactive web-based application 260 
at http://data.ohdsi.org/UkaTkaSafetyEffectiveness.  261 
Discussion 262 
In summary, compared to TKR, UKR was associated with a reduced risk of post-operative opioid use. 263 
This may indicate that UKR has a lower risk of post-operative persistent pain. UKR was also 264 
associated with a decreased risk of post-operative venous thromboembolism. There was insufficient 265 
evidence to conclude there UKR led to a reduction in risk of infection, readmission, or mortality. TKR 266 
was associated with a lower risk of revision. 267 
The primary outcome in TOPKAT was patient-reported pain and function, as measured by OKS. 268 
Outcome scores were broadly similar for the two comparator groups. The mean difference at five 269 
years was 1.04 in favour of UKR but this was not statistically significant, with a 95% confidence 270 
interval spanning -0.42 to 2.50,6 and unlikely to be clinically meaningful with the minimal important 271 
difference in OKS being 5 points.19 This finding is in accordance with previous research that has also 272 
generally found UKR and TKR to result in broadly similar gains in patient-reported outcomes after 273 
surgery.2 In this study, however, we found UKR to have a lower risk of opioid use, with the absolute 274 
effect particularly pronounced for study participants in the US. This suggests that UKR may be 275 
associated with a lower risk of persistent pain after surgery. Although few studies have previously 276 
assessed procedure choice and opioid use, our findings are consistent with two studies that 277 
have.20,21  278 
There were fewer post-operative complications for those who received UKR in TOPKAT, with UKR 279 
associated with a relative risk reduction of 28% (95% CI: 47% to 2%).6 This finding is line with those 280 
from previous observational studies, where UKR has been associated with a reduced risk for a range 281 
of complications relative to TKR.2,22–24 In particular, a meta-analysis of previous studies of national or 282 
large multicentre databases or of joint registry data found UKR to be associated with a risk ratios of 283 
0.39 (0.27 to 0.57) for venous thromboembolism and 0.27 (0.16 to 0.45) for mortality relative to 284 
TKR.2 The results from this study confirm the risk reduction for venous thromboembolism. This risk 285 
reduction appears most pronounced for older patients, with the largest effect of procedure seen in 286 
MDCR. However, with mortality only available in two databases, there was insufficient evidence to 287 
conclude there was a reduction in risk of mortality for UKR in this study. Prior observational studies 288 
have typically accounted for differences in the observed characteristics of those undergoing the two 289 
procedures, either through propensity score matching or multivariable regression. It is notable that 290 
the additional calibration on control outcomes used in this study generally led to associations in 291 
favour of UKR being somewhat attenuated. 292 
UKR and TKR were seen to have similar rates of revision in TOPKAT, with rates of revision around 4% 293 
at 5 years for both procedures.6 This finding is in contrast to much of the body of previous 294 
observational research, which have consistently found UKR to have a higher risk of revision.2,4,22,25,26 295 
Indeed, while risk of revision over 5 years after UKR is currently around 6% in the UK, risk for TKR is 296 
approximately 2.5%.26 The incidence of revision for study participants from the UK included in this 297 
study are in line with these previous findings, with revision risks seen to be slightly higher for study 298 
participants from the US. As with previous observational studies, UKR was also consistently 299 
associated with an increased risk of revision in this study. UKR can therefore be expected to have a 300 
higher risk of revision than TKR. 301 
This analysis has been informed by data from 280,000 patients across 5 databases in 2 countries. 302 
This retrospective analysis relied though on data captured in electronic health records and 303 
administrative claims, and therefore our ability to emulate the inclusion criteria used the TOPKAT 304 
trial was limited. In particular, these data did not have radiographic information and so it was not 305 
possible to assess whether an individual’s osteoarthritis was confined to one compartment of the 306 
knee. Patient-reported outcomes, the primary outcome in TOPKAT, was also not captured in the 307 
databases used and so opioid use was used as a proxy for persistent pain. This has limitations, 308 
however, as opioids may not necessarily have been taken even if dispensed. We used large-scale 309 
propensity score matching to balance the two cohorts using more than 10,000 candidate baseline 310 
characteristics. However, as with all observational studies, there remains the potential risk of 311 
confounding due to unmeasured factors. We employed a large panel of negative control outcomes 312 
to mitigate the threat of systematic error. While the definitions for exposures and outcomes were 313 
clinically reviewed and relied on codes used in prior published studies,20,27–30 individual cases were 314 
not validated and may be subject to misclassification. There may be measurement errors, for 315 
example with baseline characteristics, such as comorbidities, and outcomes, such as revision, 316 
potentially not recorded within the databases, in which case they would also be missed in the 317 
analysis. As patients in this study were selected on the basis of their inclusion criteria for the TOPKAT 318 
trial, the results from this study may also not necessarily generalise to those patients excluded from 319 
the trial but are eligible for both procedures. In addition, while meta-analysis was used to combine 320 
findings across databases, in a number of cases substantial heterogeneity was present and so the 321 
resulting estimates should be interpreted with caution. 322 
In conclusion, with a lower risk of post-operative opioid use, UKR may be associated with a reduced 323 
risk of persistent pain compared to TKR. UKR is also associated with a lower risk of venous 324 
thromboembolism. UKR is also, however, associated with an increased risk of revision. The merit of 325 
using real-world data for assessing the effectiveness of treatments is still debated,31,32 and 326 
randomised controlled trials remain the ‘gold standard’ for establishing efficacy. This study has 327 
demonstrated the value of real-world evidence for complementing the evidence produced from 328 
randomised trials. 329 
 330 
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Figure 1. Effect of procedure choice (UKR or TKR) on post-operative complications, 449 
opioid use, and revision 450 
Numbers of propensity score matched individuals, observed events, HRs and cHRs for UKR relative 451 
TKR. Readmission data were not available in PharMetrics and THIN. Mortality data were only 452 
available in Optum and THIN. Calibration of hazard ratios was infeasible for post-operative 453 
complications in THIN because there were too few negative control events observed during the 60-454 
day time-at-risk. Adjusted HRs account for residual confounding identified by negative control 455 
outcomes analyses. Calibrated HRs were not estimated for 60-day outcomes in THIN due to too few 456 
control outcomes being observed. UKR: unicompartmental knee replacement; TKR: total knee 457 
replacement; HR: Hazard ratio; CI: confidence interval; IR: incidence rate; VTE: venous 458 
thromboembolism; MDCR: Medicare Supplemental Database; CCAE: Commercial Database; Optum: 459 
Optum De-Identified Clinformatics Data Mart Database; PharMetrics: PharMetrics™ Plus; THIN: The 460 













Table 1. Selected patient characteristics after propensity score matching 474 
 475 























N 7,779 58,290  4,093 34,836  5,750 43,612  1,980 15,123  12,777 98,516  
Age group                
    40-44 2.9 2.6 0.02       1.5 1.2 0.03 1.3 0.8 0.05 2.3 2.2 0.01 
    45-49 8.2 8.0 0.00       4.3 4.3 0.00 5.4 5.5 0.00 6.8 7.2 -0.02 
    50-54 19.0 19.1 0.00 <0.1 0.1 -0.01 8.8 9.4 -0.02 10.3 11.0 -0.02 14.6 15.0 -0.01 
    55-59 29.3 28.3 0.02 0.2 0.4 -0.05 12.8 14.0 -0.03 13.9 16.1 -0.06 22.5 22.9 -0.01 
    60-64 37.5 38.8 -0.03 0.7 1.2 -0.06 16.0 17.0 -0.03 18.7 20.1 -0.04 27.1 26.9 0.00 
    65-69 3.1 3.1 0.00 26.9 27.3 -0.01 17.3 17.5 -0.01 18.5 18.1 0.01 12.2 12.0 0.01 
    70-74       29.2 29.0 0.00 16.6 15.9 0.02 14.2 12.9 0.04 7.5 7.1 0.02 
    75-79       22.2 21.9 0.01 12.1 11.1 0.03 10.5 9.0 0.05 5.9 5.9 0.00 
    80-84       14.1 14.1 0.00 7.8 7.3 0.02 4.9 4.2 0.03 1.1 0.8 0.02 
    85-89       5.8 5.2 0.03 2.8 2.3 0.03 1.8 2.0 -0.02       
    90-94       0.9 0.7 0.02       0.5 0.3 0.03       
Gender: female 52.8 53.3 -0.01 47.1 47.9 -0.02 48.3 48.2 0.00 51.4 51.3 0.00 49.4 49.0 0.01 
Medical history: 
General 
                                                  
    Atrial fibrillation 2.3 2.5 -0.01 10.9 10.5 0.02 7.4 7.0 0.02 1.8 2.1 -0.02 4.6 4.3 0.02 
    Chronic 
obstructive lung 
disease 
3.7 3.3 0.02 10.2 10.4 -0.01 7.8 7.5 0.01 1.7 1.6 0.01 5.1 5.0 0.00 
    Depressive 
disorder 
12.2 12.2 0.00 7.9 7.3 0.02 14.4 14.2 0.00 3.8 4.6 -0.04 13.1 13.5 -0.01 
    Diabetes 
mellitus 
17.7 17.1 0.02 24.3 23.1 0.03 22.3 20.7 0.04 4.0 4.1 0.00 18.7 18.0 0.02 
    Hyperlipidemia 55.3 54.9 0.01 59.0 57.9 0.02 70.6 68.8 0.04 4.9 4.0 0.05 61.0 60.4 0.01 
    Hypertensive 
disorder 
56.7 55.4 0.03 72.0 70.2 0.04 68.5 65.6 0.06 10.5 9.9 0.02 60.9 60.1 0.02 
    Obesity 13.5 13.6 0.00 6.1 6.0 0.00 17.8 17.1 0.02 2.1 1.9 0.01       
    Osteoarthritis 90.2 90.2 0.00 89.4 89.0 0.01 92.6 92.6 0.00 48.1 44.9 0.06 91.1 91.4 -0.01 
    Renal 
impairment 
2.7 2.7 0.00 8.1 7.2 0.03 9.5 9.0 0.02 4.8 4.5 0.02 3.8 3.7 0.00 
    Peripheral 
vascular disease 
10.1 9.9 0.01 27.7 26.5 0.02 20.4 19.6 0.02 3.6 3.0 0.03 14.0 13.3 0.02 
    Pulmonary 
embolism 
0.5 0.5 0.00 0.7 0.9 -0.02 0.8 0.9 0.00 0.3 0.4 -0.02 0.7 0.6 0.01 
    Venous 
thrombosis 
2.4 2.6 -0.01 4.4 4.4 0.00 2.8 3.1 -0.02 2.8 2.2 0.04 3.0 2.9 0.00 
Medication use                                                   
    Antibacterials for 
systemic use 
75.8 75.5 0.01 76.9 76.6 0.01 68.8 68.2 0.01 10.1 9.6 0.02 61.3 61.8 -0.01 
    Antidepressants 29.6 29.4 0.00 22.9 22.2 0.02 23.4 23.7 -0.01 0.5 0.9 -0.04 23.0 23.2 -0.01 




62.1 61.9 0.00 53.2 53.2 0.00 50.6 49.9 0.01 1.6 1.8 -0.01 47.6 47.8 0.00 
    Antithrombotic 
agents 
17.7 17.7 0.00 26.6 25.9 0.02 19.3 19.3 0.00 1.8 1.2 0.06 14.1 14.0 0.00 
    Opioids 44.2 44.2 0.00 38.9 38.9 0.00 39.2 39.2 0.00 <0.3 0.5 -0.05 30.9 31.3 -0.01 
Select characteristics after propensity score matching, showing the weighted percentage of subjects with the characteristics in the UKR and TKR cohorts. 476 
UKR: unicompartmental knee replacement; TKR: total knee replacement; SMD: standardised mean difference; MDCR: Medicare Supplemental Database; 477 
CCAE: Commercial Database; Optum: Optum De-Identified Clinformatics Data Mart Database; THIN: The Health Improvement Network; PharMetrics: 478 
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Table A1. Negative control outcomes  
1 Acquired hallux malleus 21 Hyperlipidemia 
2 Acquired hallux valgus 22 Hypermetropia 
3 Acquired trigger finger 23 Hypothyroidism 
4 Allergic rhinitis 24 Impacted cerumen 
5 Astigmatism 25 Kidney stone 
6 Benign neoplasm of colon 26 Menopausal syndrome 
7 Breast lump 27 Nicotine dependence 
8 Carpal tunnel syndrome 28 Otitis media 
9 Cataract 29 Presbyopia 
10 Chronic obstructive lung disease 30 Rosacea 
11 Diaphragmatic hernia 31 Sleep apnea 
12 Disorder of brain 32 Tear film insufficiency 
13 Disorder of breast 33 Tinnitus 
14 Disorder of lung 34 Type 2 diabetes mellitus 
15 Diverticular disease of colon 35 Uncomplicated asthma 
16 Essential hypertension 36 Urinary incontinence 
17 Gastroesophageal reflux disease with 
esophagitis 
37 Vitamin B deficiency 
18 Gastroesophageal reflux disease 38 Vitamin D deficiency 
19 Glaucoma 39 Wrist joint pain 





Table A2. Tabulation of sensitivity analyses 
 





Primary 60 days 1:10 variable None 
Sensitivity 
1 year 1:10 variable None 
5 years 1:10 variable None 
60 days 1:10 variable 5% 
60 days 1:1 None 
Revision 
Primary 5 years 1:10 variable None 
Sensitivity 
1 year 1:10 variable None 
5 years 1:10 variable 5% 
5 years 1:1 None 
Opioid use 
Primary 91 days-1 year 1:10 variable None 
Sensitivity 
91 days-5 years 1:10 variable None 
91 days-1 year 1:10 variable 5% 














60 days 1:10 variable None 
1 year 1:10 variable None 
5 years 1:10 variable None 
60 days 1:10 variable 5% 
60 days 1:1 None 
Revision Sensitivity 
5 years 1:10 variable None 
1 year 1:10 variable None 
5 years 1:10 variable 5% 
5 years 1:1 None 
Opioid use Sensitivity 
91 days-1 year 1:10 variable None 
91 days-5 years 1:10 variable None 
91 days-1 year 1:10 variable 5% 





Figure A1. Study flow charts 
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Table A3. Patient characteristics before propensity score matching 























Age group                
    40-44 3.0 1.1 0.13    1.5 0.5 0.10 1.3 0.4 0.11 2.4 0.8 0.12 
    45-49 8.2 4.6 0.15    4.4 1.8 0.16 5.4 1.3 0.23 6.9 3.2 0.17 
    50-54 19.1 14.0 0.14 <0.1 0.1 0.00 8.9 5.0 0.15 10.3 3.9 0.25 14.7 10.1 0.14 
    55-59 29.4 30.2 -0.02 0.2 0.3 -0.01 12.9 10.2 0.09 13.9 7.9 0.19 22.7 20.8 0.05 
    60-64 37.4 45.7 -0.17 0.7 0.7 0.00 16.1 14.5 0.05 18.7 14.2 0.12 27.0 30.3 -0.08 
    65-69 3.1 4.3 -0.07 27.1 24.2 0.07 17.2 19.1 -0.05 18.4 18.9 -0.01 12.1 15.1 -0.09 
    70-74    29.2 28.6 0.01 16.5 20.2 -0.10 14.2 19.6 -0.15 7.3 10.6 -0.12 
    75-79    22.0 24.4 -0.06 11.8 16.5 -0.13 10.4 17.9 -0.22 5.9 7.9 -0.08 
    80-84    14.0 15.5 -0.04 7.7 10.0 -0.08 4.9 11.0 -0.23 1.1 1.1 0.00 
    85-89    5.7 5.5 0.01 2.9 2.3 0.03 1.8 4.3 -0.15    
    90-94    0.9 0.7 0.02    0.5 0.5 0.00    
Gender: female 52.8 57.1 -0.09 46.4 58.3 -0.24 48.3 58.0 -0.20 51.3 56.6 -0.11 49.0 55.7 -0.13 
Medical history: 
General                                                   
    Atrial fibrillation 2.3 3.7 -0.08 10.8 11.7 -0.03 7.3 9.2 -0.07 1.8 3.2 -0.09 4.6 6.2 -0.07 
    Chronic 
obstructive lung 
disease 3.7 4.2 -0.03 10.2 11.2 -0.03 7.7 9.5 -0.06 1.7 2.3 -0.05 5.0 6.4 -0.06 
    Depressive 
disorder 12.2 12.6 -0.01 7.9 7.8 0.00 14.4 14.6 0.00 3.8 3.9 -0.01 13.1 13.8 -0.02 
    Diabetes 
mellitus 17.4 23.5 -0.15 24.1 27.1 -0.07 22.2 27.8 -0.13 4.0 6.4 -0.11 18.6 24.7 -0.15 
    Hyperlipidemia 55.2 57.5 -0.05 59.2 55.9 0.07 70.4 72.6 -0.05 5.0 4.2 0.04 61.0 63.9 -0.06 
    Hypertensive 
disorder 56.3 65.4 -0.19 71.9 76.1 -0.10 68.2 76.9 -0.20 10.5 12.0 -0.05 60.6 69.7 -0.19 
    Obesity 13.4 20.0 -0.18 6.1 9.2 -0.12 17.8 23.2 -0.13 2.1 2.0 0.01    
22 
 
    Osteoarthritis 90.3 91.1 -0.02 89.4 89.7 -0.01 92.7 93.9 -0.05 48.1 53.1 -0.10 91.2 91.9 -0.02 
    Renal 
impairment 2.7 3.7 -0.06 8.0 8.7 -0.02 9.4 11.7 -0.08 4.8 7.9 -0.13 3.7 5.5 -0.08 
    Peripheral 
vascular disease 10.2 12.7 -0.08 27.6 28.5 -0.02 20.4 24.4 -0.10 3.6 3.8 -0.01 13.7 17.6 -0.10 
    Pulmonary 
embolism 0.5 0.8 -0.04 0.6 1.2 -0.06 0.8 1.2 -0.04 0.3 0.4 -0.02 0.7 0.9 -0.02 
    Venous 
thrombosis 2.4 3.3 -0.05 4.5 5.3 -0.04 2.8 4.3 -0.08 2.8 2.7 0.01 3.0 3.8 -0.04 
Medication use                                                   
    Antibacterials for 
systemic use 75.7 75.6 0.00 76.9 78.0 -0.03 69.1 67.9 0.03 10.1 10.8 -0.02 61.3 62.8 -0.03 
    Antidepressants 29.6 29.9 -0.01 22.9 24.4 -0.04 23.4 23.5 0.00 0.5 0.9 -0.05 22.9 23.1 0.00 
    
Antiinflammatory 
and antirheumatic 
products 62.2 63.7 -0.03 53.3 56.3 -0.06 50.9 50.0 0.02 1.6 1.7 -0.01 47.5 48.0 -0.01 
    Antithrombotic 
agents 17.6 21.2 -0.09 26.4 29.7 -0.08 19.3 22.2 -0.07 1.8 1.8 0.00 13.8 17.7 -0.11 
    Opioids 44.2 45.9 -0.04 39.0 42.8 -0.08 39.4 40.2 -0.02 <0.3 0.6 -0.06 30.9 32.1 -0.03 
Select characteristics after propensity score matching, showing the weighted percentage of subjects with the characteristics in the UKR and TKR cohorts. 
UKR: unicompartmental knee replacement; TKR: total knee replacement; SMD: standardised mean difference; MDCR: Medicare Supplemental Database; 





Figure A2. Diagnostics for primary analysis by database 
The first column is the preference score distribution of the UKR and TKR cohorts. The preference score is a transformation of the propensity score that 
adjusts for differences in the sizes of the two treatment groups. A higher overlap indicates subjects in the two groups were more similar in terms of their 
predicted probability of receiving one treatment over the other. The second column represents covariate balance before and after matching. Each dot 
represents the standardizes difference of means for a single covariate before and after matching on the propensity score. The third, fourth, and fifth 
columns are the effect estimates of negative control outcomes during 60 day, 91 day to 1 year, and 5 year time-at-risk, respectively. Each blue dot 
represents the estimated hazard ratio and standard error (related to the width of the confidence interval) of each of the negative control outcomes. 






Figure A3. Kaplan-Meier estimates for opioid use (from 91 days after surgery to 1 
year) and revision (from day of surgery to 5 years) following unicompartmental knee 





Table A4. Results from all analyses 
Outcome  Source 
Analysis 
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10:1 variable ratio matching, 60 day time-at-risk; without prior 
spine-hip-foot pathology restriction 
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Mortality thin Primary 10:1 variable ratio matching, 60 day time-at-risk 
<5 







ty 10:1 variable ratio matching, 1 year time-at-risk 9 (4.83) 84 (5.86) 
0.96 (0.45 
- 1.81) 















ty 10:1 variable ratio matching 5% trim, 60 day time-at-risk 
<5 



















10:1 variable ratio matching, 60 day time-at-risk; without prior 
spine-hip-foot pathology restriction 
<5 








10:1 variable ratio matching, 1 year time-at-risk; without prior 
spine-hip-foot pathology restriction 
11 








10:1 variable ratio matching, 5 year time-at-risk; without prior 












10:1 variable ratio matching 5% trim, 60 day time-at-risk; without 
prior spine-hip-foot pathology restriction 
<5 










1:1 ratio matching, 60 day time-at-risk; without prior spine-hip-

































































10:1 variable ratio matching, 60 day time-at-risk; without prior 










10:1 variable ratio matching, 1 year time-at-risk; without prior 














10:1 variable ratio matching, 5 year time-at-risk; without prior 














10:1 variable ratio matching 5% trim, 60 day time-at-risk; without 










1:1 ratio matching, 60 day time-at-risk; without prior spine-hip-














Opioid use CCAE 
Sensitivi









Opioid use CCAE 
Sensitivi
ty 










Opioid use CCAE 
Sensitivi









Opioid use CCAE 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 1 year time-at-risk; 











Opioid use CCAE 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 5 years time-at-risk; 









Opioid use CCAE 
Sensitivi
ty 
10:1 variable ratio matching 5% trim, 91 days to 1 year time-at-









Opioid use CCAE 
Sensitivi
ty 
1:1 ratio matching, 91 days to 1 year time-at-risk; without prior 


















Opioid use MDCR 
Sensitivi









Opioid use MDCR 
Sensitivi
ty 










Opioid use MDCR 
Sensitivi









Opioid use MDCR 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 1 year time-at-risk; 









Opioid use MDCR 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 5 years time-at-risk; 









Opioid use MDCR 
Sensitivi
ty 
10:1 variable ratio matching 5% trim, 91 days to 1 year time-at-









Opioid use MDCR 
Sensitivi
ty 
1:1 ratio matching, 91 days to 1 year time-at-risk; without prior 


















Opioid use Optum 
Sensitivi









Opioid use Optum 
Sensitivi
ty 










Opioid use Optum 
Sensitivi









Opioid use Optum 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 1 year time-at-risk; 











Opioid use Optum 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 5 years time-at-risk; 









Opioid use Optum 
Sensitivi
ty 
10:1 variable ratio matching 5% trim, 91 days to 1 year time-at-









Opioid use Optum 
Sensitivi
ty 
1:1 ratio matching, 91 days to 1 year time-at-risk; without prior 


















Opioid use thin 
Sensitivi









Opioid use thin 
Sensitivi
ty 










Opioid use thin 
Sensitivi









Opioid use thin 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 1 year time-at-risk; 









Opioid use thin 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 5 years time-at-risk; 









Opioid use thin 
Sensitivi
ty 
10:1 variable ratio matching 5% trim, 91 days to 1 year time-at-









Opioid use thin 
Sensitivi
ty 
1:1 ratio matching, 91 days to 1 year time-at-risk; without prior 


















Opioid use pmtx 
Sensitivi









Opioid use pmtx 
Sensitivi
ty 










Opioid use pmtx 
Sensitivi









Opioid use pmtx 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 1 year time-at-risk; 











Opioid use pmtx 
Sensitivi
ty 
10:1 variable ratio matching, 91 days to 5 years time-at-risk; 









Opioid use pmtx 
Sensitivi
ty 
10:1 variable ratio matching 5% trim, 91 days to 1 year time-at-









Opioid use pmtx 
Sensitivi
ty 
1:1 ratio matching, 91 days to 1 year time-at-risk; without prior 


































































10:1 variable ratio matching, 91 days to 1 year time-at-risk; 














10:1 variable ratio matching, 91 days to 5 years time-at-risk; 














10:1 variable ratio matching 5% trim, 91 days to 1 year time-at-














1:1 ratio matching, 91 days to 1 year time-at-risk; without prior 






















































10:1 variable ratio matching, 1 year time-at-risk; without prior 














10:1 variable ratio matching, 5 year time-at-risk; without prior 












10:1 variable ratio matching 5% trim, 5 year time-at-risk; without 












1:1 ratio matching, 5 year time-at-risk; without prior spine-hip-










































ty 1:1 ratio matching, 5 year time-at-risk 
145 








10:1 variable ratio matching, 1 year time-at-risk; without prior 












10:1 variable ratio matching, 5 year time-at-risk; without prior 












10:1 variable ratio matching 5% trim, 5 year time-at-risk; without 












1:1 ratio matching, 5 year time-at-risk; without prior spine-hip-
foot pathology restriction 
179 


















































10:1 variable ratio matching, 1 year time-at-risk; without prior 














10:1 variable ratio matching, 5 year time-at-risk; without prior 












10:1 variable ratio matching 5% trim, 5 year time-at-risk; without 












1:1 ratio matching, 5 year time-at-risk; without prior spine-hip-




















ty 10:1 variable ratio matching, 1 year time-at-risk 
18 
(9.71) 48 (3.35) 
2.42 (1.34 
- 4.20) 















ty 1:1 ratio matching, 5 year time-at-risk 
51 








10:1 variable ratio matching, 1 year time-at-risk; without prior 
spine-hip-foot pathology restriction 
21 








10:1 variable ratio matching, 5 year time-at-risk; without prior 












10:1 variable ratio matching 5% trim, 5 year time-at-risk; without 












1:1 ratio matching, 5 year time-at-risk; without prior spine-hip-
foot pathology restriction 
61 


















































10:1 variable ratio matching, 1 year time-at-risk; without prior 














10:1 variable ratio matching, 5 year time-at-risk; without prior 












10:1 variable ratio matching 5% trim, 5 year time-at-risk; without 












1:1 ratio matching, 5 year time-at-risk; without prior spine-hip-
































































10:1 variable ratio matching, 1 year time-at-risk; without prior 














10:1 variable ratio matching, 5 year time-at-risk; without prior 














10:1 variable ratio matching 5% trim, 5 year time-at-risk; without 














1:1 ratio matching, 5 year time-at-risk; without prior spine-hip-
foot pathology restriction 
1,419 
(14.96) 
998 
(10.50) 
1.39 (1.26 
- 1.54) 
1.37 (1.15 
- 1.68) 
 
 
